

## Publications

1. de Gasparo M, Hess P, Clozel M, Persohn E, Roman D, Germann PG, Clozel JP and Webb RL (2002) Combination of low-dose valsartan and enalapril improves endothelial dysfunction and coronary reserve in Nomega-nitro-L-arginine methyl ester-treated spontaneously hypertensive rats. *J Cardiovasc Pharmacol* **40**:789-800.
2. Ding SS, Qiu C, Hess P, Xi JF, Clozel JP and Clozel M (2002) Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure. *Cardiovasc Res* **53**:963-970.
3. Clozel M, Qiu C, Qiu CS, Hess P and Clozel JP (2002) Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. *J Am Coll Cardiol* **39**:142-147.
4. Qiu C, Ding SS, Hess P, Clozel JP and Clozel M (2001a) Endothelin mediates the altered renal hemodynamics associated with experimental congestive heart failure. *J Cardiovasc Pharmacol* **38**:317-324.
5. Qiu CB, Qiu CS, Hess P, Clozel JP and Clozel M (2001b) Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure. *Acta Pharmacol Sin* **22**:541-548.
6. Marki HP, Binggeli A, Bittner B, Bohner-Lang V, Breu V, Bur D, Coassolo PH, Clozel JP, D'Arcy A, Doebeli H, Fischli W, Funk CH, Foricher J, Giller T, Gruninger F, Guenzi A, Guller R, Hartung T, Hirth G, Jenny CH, Kansy M, Klinkhammer U, Lave T, Lohri B, Luft FC, Mervaala EM, Muller DN, Muller M, Montavon F, Oefner CH, Qiu C, Reichel A, Sanwald-Ducray P, Scalone M, Schleimer M, Schmid R, Stadler H, Treiber A, Valdenaire O, Vieira E, Waldmeier P, Wiegand-Chou R, Wilhelm M, Westl W, Zell M and Zell R (2001) Piperidine renin inhibitors: from leads to drug candidates. *Farmaco* **56**:21-27.
7. de Gasparo M, Hess P, Nuesslein-Hildesheim B, Bruneval P and Clozel JP (2000) Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction. *J Renin Angiotensin Aldosterone Syst* **1**:151-158.
8. Operschall C, Falivene L, Clozel JP and Roux S (2000) A new model of chronic cardiac ischemia in rabbits. *J Appl Physiol* **88**:1438-1445.
9. du Souich P, Besner JG, Clozel JP, Welker HA, Lefebvre M and Caille G (2000) Nonlinear kinetics and pharmacologic response to mibefradil. *Clin Pharmacol Ther* **67**:249-257.
10. Clozel JP, Veniant MM, Qiu C, Sprecher U, Wolfgang R and Fischli W (1999a) Renal vascular and biochemical responses to systemic renin inhibition in dogs at low renal perfusion pressure. *J Cardiovasc Pharmacol* **34**:674-682.
11. Karam H, Clozel JP, Bruneval P, Gonzalez MF and Menard J (1999) Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats. *Hypertension* **34**:673-678.

12. Clozel JP, Ertel EA and Ertel SI (1999b) Voltage-gated T-type Ca<sup>2+</sup> channels and heart failure. *Proc Assoc Am Physicians* **111**:429-437.
13. Roux S, Qiu C, Sprecher U, Osterwalder R and Clozel JP (1999) Protective effects of endothelin receptor antagonists in dogs with aortic cross-clamping. *J Cardiovasc Pharmacol* **34**:199-205.
14. Clozel M, Ramuz H, Clozel JP, Breu V, Hess P, Loffler BM, Coassolo P and Roux S (1999c) Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. *J Pharmacol Exp Ther* **290**:840-846.
15. Clozel M, Qiu C, Osterwalder R, Roedel A, Bruneval P, Heudes D and Clozel JP (1999d) Effects of nonpeptide endothelin receptor antagonists in rats with reduced renal mass. *J Cardiovasc Pharmacol* **33**:611-618.
16. Oefner C, Binggeli A, Breu V, Bur D, Clozel JP, D'Arcy A, Dorn A, Fischli W, Gruninger F, Guller R, Hirth G, Marki H, Mathews S, M MI, Ridley RG, Stadler H, Vieira E, Wilhelm M, Winkler F and Wostl W (1999) Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases? *Chem Biol* **6**:127-131.
17. Costerousse O, Allegrini J, Clozel JP, Menard J and Alhenc-Gelas F (1998) Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia. *J Pharmacol Exp Ther* **284**:1180-1187.
18. Muller DN, Fischli W, Clozel JP, Hilgers KF, Bohlender J, Menard J, Busjahn A, Ganten D and Luft FC (1998) Local angiotensin II generation in the rat heart: role of renin uptake. *Circ Res* **82**:13-20.
19. Ertel SI, Ertel EA and Clozel JP (1997) T-type Ca<sup>2+</sup> channels and pharmacological blockade: potential pathophysiological relevance. *Cardiovasc Drugs Ther* **11**:723-739.
20. Clozel JP, Ertel EA and Ertel SI (1997) Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. *J Hypertens Suppl* **15**:S17-25.
21. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, Clozel JP and Clozel M (1997) Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. *J Pharmacol Exp Ther* **283**:1110-1118.
22. Donckier JE, Massart PE, Hodeige D, Van Mechelen H, Clozel JP, Laloux O, Ketelslegers JM, Charlier AA and Heyndrickx GR (1997) Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition. *Circulation* **96**:1250-1256.
23. Ertel SI and Clozel JP (1997) Mibefradil (Ro 40-5967): the first selective T-type Ca<sup>2+</sup> channel blocker. *Expert Opin Investig Drugs* **6**:569-582.

24. Scott WJ, Jr., Resnick E, Hummler H, Clozel JP and Burgin H (1997) Cardiovascular alterations in rat fetuses exposed to calcium channel blockers. *Reprod Toxicol* **11**:207-214.
25. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, Kiowski W and Fischli W (1997) Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. *Circ Res* **80**:219-227.
26. Mulder P, Richard V, Compagnon P, Henry JP, Lallemand F, Clozel JP, Koen R, Mace B and Thuillez C (1997) Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. *J Am Coll Cardiol* **29**:416-421.
27. Karam H, Heudes D, Gonzales MF, Loffler BM, Clozel M and Clozel JP (1996a) Respective role of humoral factors and blood pressure in aortic remodeling of DOCA hypertensive rats. *Am J Hypertens* **9**:991-998.
28. Karam H, Heudes D, Bruneval P, Gonzales MF, Loffler BM, Clozel M and Clozel JP (1996b) Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism. *Hypertension* **28**:379-385.
29. Hess P, Clozel M and Clozel JP (1996) Telemetry monitoring of pulmonary arterial pressure in freely moving rats. *J Appl Physiol* **81**:1027-1032.
30. Watanabe H, Clozel M and Clozel JP (1996) Nimodipine does not increase cerebral blood flow during subarachnoid hemorrhage in the rat. *Pharmacology* **53**:1-10.
31. Schmitt R, Clozel JP, Iberg N and Buhler FR (1996) Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition. *Cardiovasc Drugs Ther* **10**:101-105.
32. Vacher E, Richer C, Fornes P, Clozel JP and Giudicelli (1996) Mibefradil, a selective calcium T-channel blocker, in stroke-prone spontaneously hypertensive rats. *J Cardiovasc Pharmacol* **27**:686-694.
33. Coassolo P, Fischli W, Clozel JP and Chou RC (1996) Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog and primates. *Xenobiotica* **26**:333-345.
34. Karam H, Heudes D, Hess P, Gonzales MF, Loffler BM, Clozel M and Clozel JP (1996c) Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats. *Cardiovasc Res* **31**:287-295.
35. Dagassan PH, Breu V, Clozel M, Kunzli A, Vogt P, Turina M, Kiowski W and Clozel JP (1996) Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. *J Cardiovasc Pharmacol* **27**:147-153.
36. Roux S, Buhler M and Clozel JP (1996) Mechanism of the antiischemic effect of mibefradil, a selective T calcium channel blocker in dogs: comparison with amlodipine. *J Cardiovasc Pharmacol* **27**:132-139.

37. Hahn M, Tkachuk VA, Bochkov VN, Cheglakov IB and Clozel JP (1995) Blockade of receptor-operated calcium channels by mibefradil (Ro 40-5967): effects on intracellular calcium and platelet aggregation. *Cardiovasc Drugs Ther* **9**:815-821.
38. Clozel JP, Veniant M, Sprecher U and Fischli W (1995) Acute hemodynamic effects of ciprokiren, a novel renin inhibitor, in sodium-depleted dogs. *J Cardiovasc Pharmacol* **26**:674-677.
39. Schmitt R, Clozel JP, Iberg N and Buhler FR (1995) Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel. *Arterioscler Thromb Vasc Biol* **15**:1161-1165.
40. Kung CF, Tschudi MR, Noll G, Clozel JP and Luscher TF (1995) Differential effects of the calcium antagonist mibefradil in epicardial and intramyocardial coronary arteries. *J Cardiovasc Pharmacol* **26**:312-318.
41. Donckier J, Stoleru L, Hayashida W, Van Mechelen H, Selvais P, Galanti L, Clozel JP, Ketelslegers JM and Pouleur H (1995) Role of endogenous endothelin-1 in experimental renal hypertension in dogs. *Circulation* **92**:106-113.
42. Veniant M, Gray GA, Heudes D, Menard J and Clozel JP (1995) Structural changes and cyclic GMP content of the aorta after calcium antagonism or angiotensin converting enzyme inhibition in renovascular hypertensive rats. *J Hypertens* **13**:731-737.
43. Roux S, Clozel M, Wolfgang R, Sprecher U and Clozel JP (1995a) Comparative evaluation of acute cerebral vasospasm by the microsphere and the angiography techniques. *J Neurosci Methods* **59**:245-252.
44. Karam H, Bruneval P, Clozel JP, Loffler BM, Bariety J and Clozel M (1995) Role of endothelin in acute renal failure due to rhabdomyolysis in rats. *J Pharmacol Exp Ther* **274**:481-486.
45. Roux S, Loffler BM, Gray GA, Sprecher U, Clozel M and Clozel JP (1995b) The role of endothelin in experimental cerebral vasospasm. *Neurosurgery* **37**:78-85; discussion 85-76.
46. Teerlink JR, Carteaux JP, Sprecher U, Loffler BM, Clozel M and Clozel JP (1995) Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. *Am J Physiol* **268**:H432-440.
47. Dagassan PH, Clozel M, Breu V and Clozel JP (1995) Role of endothelin in spontaneous phasic contraction of human coronary arteries. *J Cardiovasc Pharmacol* **26 Suppl 3**:S200-203.
48. Dagassan PH, Breu V, Clozel M and Clozel JP (1994) Role of endothelin during reperfusion after ischemia in isolated perfused rat heart. *J Cardiovasc Pharmacol* **24**:867-874.

49. Teerlink JR, Loffler BM, Hess P, Maire JP, Clozel M and Clozel JP (1994a) Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). *Circulation* **90**:2510-2518.
50. Fischli W, Clozel JP, Breu V, Buchmann S, Mathews S, Stadler H, Vieira E and Wostl W (1994) Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment. *Hypertension* **24**:163-169.
51. Veniant M, Heudes D, Clozel JP, Bruneval P and Menard J (1994a) Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats. *Kidney Int* **46**:421-429.
52. Boulanger CM, Desta B, Clozel JP and Vanhoutte PM (1994) Chronic treatment with the CA<sub>2</sub><sup>+</sup> channel inhibitor RO 40-5967 potentiates endothelium-dependent relaxations in the aorta of the hypertensive salt sensitive Dahl rat. *Blood Press* **3**:193-196.
53. Eng E, Veniant M, Floege J, Fingerle J, Alpers CE, Menard J, Clozel JP and Johnson RJ (1994) Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. *Am J Hypertens* **7**:177-185.
54. Roux S, Carteaux JP, Hess P, Falivene L and Clozel JP (1994) Experimental carotid thrombosis in the guinea pig. *Thromb Haemost* **71**:252-256.
55. Teerlink JR, Breu V, Sprecher U, Clozel M and Clozel JP (1994b) Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. *Circ Res* **74**:105-114.
56. Teerlink JR, Gray GA, Clozel M and Clozel JP (1994c) Increased vascular responsiveness to norepinephrine in rats with heart failure is endothelium dependent. Dissociation of basal and stimulated nitric oxide release. *Circulation* **89**:393-401.
57. Clozel JP, Hess P, Schietinger K, Breu V, Fischli W and Baumgartner HR (1994) Major role of the renin-angiotensin system in the neointima formation after vascular injury in guinea pigs. *Life Sci* **54**:PL87-92.
58. Veniant M, Clozel JP, Hess P and Clozel M (1994b) Endothelin plays a role in the maintenance of blood pressure in normotensive guinea pigs. *Life Sci* **55**:445-454.
59. Gray GA, Clozel M, Clozel JP and Baumgartner HR (1993) Effects of calcium channel blockade on the aortic intima in spontaneously hypertensive rats. *Hypertension* **22**:569-576.
60. Clozel JP, Muller RK, Roux S, Fischli W and Baumgartner HR (1993a) Influence of the status of the renin-angiotensin system on the effect of cilazapril on neointima formation after vascular injury in rats. *Circulation* **88**:1222-1227.
61. Teerlink JR, Clozel M, Fischli W and Clozel JP (1993) Temporal evolution of endothelial dysfunction in a rat model of chronic heart failure. *J Am Coll Cardiol* **22**:615-620.

62. Clozel JP and Fischli W (1993a) Comparative effects of three different potent renin inhibitors in primates. *Hypertension* **22**:9-17.
63. Teerlink JR and Clozel JP (1993) Hemodynamic variability and circadian rhythm in rats with heart failure: role of locomotor activity. *Am J Physiol* **264**:H2111-2118.
64. Veniant M, Clozel JP, Heudes D, Banken L and Menard J (1993a) Effects of Ro 40-5967, a new calcium antagonist, and enalapril on cardiac remodeling in renal hypertensive rats. *J Cardiovasc Pharmacol* **21**:544-551.
65. Loffler BM, Roux S, Kalina B, Clozel M and Clozel JP (1993) Influence of congestive heart failure on endothelin levels and receptors in rabbits. *J Mol Cell Cardiol* **25**:407-416.
66. Clozel JP and Fischli W (1993b) Discovery of remikiren as the first orally active renin inhibitor. *Arzneimittelforschung* **43**:260-262.
67. Veniant M, Clozel JP, Kuhn H and Clozel M (1993b) Protective effect of cilazapril on the cerebral circulation. *J Cardiovasc Pharmacol* **22 Suppl 1**:S30-35.
68. Clozel JP, Fischli W and Menard J (1993b) Effects of the blockade of the renin-angiotensin system in cyclosporin-induced hypertension. *J Hypertens* **11**:75-81.
69. Roux S, Clozel JP, Fischli W and Kuhn H (1992) Isoproterenol impairs the rat coronary vasculature: effects of angiotensin-converting enzyme inhibition. *J Cardiovasc Pharmacol* **19**:525-531.
70. Veniant M, Clozel JP, Hess P and Fischli W (1992a) Effects of renin-angiotensin system blockade in guinea pigs. *Hypertension* **19**:255-262.
71. Veniant M, Clozel JP and Fischli W (1992b) A comparison of the effects of renin inhibition and angiotensin converting enzyme inhibition upon bradykinin potentiation. *J Hypertens* **10**:155-160.
72. Veniant M, Clozel JP, Kuhn H and Clozel M (1992c) Protective effect of cilazapril on the cerebral circulation. *J Cardiovasc Pharmacol* **19 Suppl 6**:S94-99.
73. Clozel JP, Kuhn H and Hefti F (1992) Vascular protection with cilazapril in hypertension. *J Cardiovasc Pharmacol* **19 Suppl 5**:S28-33.
74. Clozel JP, Veniant M, Hess P and Sprecher U (1991a) Effects of two angiotensin converting enzyme inhibitors and hydralazine on coronary circulation in hypertensive rats. *Hypertension* **18**:118-14.
75. Osterrieder W, Muller RK, Powell JS, Clozel JP, Hefti F and Baumgartner HR (1991) Role of angiotensin II in injury-induced neointima formation in rats. *Hypertension* **18**:1160-64.
76. Clozel JP, Hess P, Michael C, Schietinger K and Baumgartner HR (1991b) Inhibition of converting enzyme and neointima formation after vascular injury in rabbits and guinea pigs. *Hypertension* **18**:1155-59.

77. Roux SP, Clozel JP and Kuhn H (1991) Cilazapril inhibits wall thickening of vein bypass graft in the rat. *Hypertension* **18**:1143-46.
78. Fischli W, Clozel JP, el Amrani K, Wostl W, Neidhart W, Stadler H and Branca Q (1991) Ro 42-5892 is a potent orally active renin inhibitor in primates. *Hypertension* **18**:22-31.
79. Clozel JP and Sprecher U (1991) Influence of low perfusion pressure on effect of endothelin on coronary vascular bed. *Am J Physiol* **260**:H893-901.
80. Veniant M, Clozel JP, Hess P and Wolfgang R (1991a) Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. *J Cardiovasc Pharmacol* **17**:277-284.
81. Clozel JP, Powell JS, Kuhn H, Muller RK, Hefti F and Baumgartner HR (1991c) Vascular protection with cilazapril. *Drugs* **41 Suppl 1**:62-67.
82. Veniant M, Clozel JP, Hess P and Wolfgang R (1991b) Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine. *J Cardiovasc Pharmacol* **18 Suppl 10**:S55-58.
83. Clozel JP, Saunier C, Hartemann D and Fischli W (1991d) Effects of cilazapril, a novel angiotensin converting enzyme inhibitor, on the structure of pulmonary arteries of rats exposed to chronic hypoxia. *J Cardiovasc Pharmacol* **17**:36-40.
84. Clozel JP, Pisarri TE, Coleridge HM and Coleridge JC (1990a) Reflex coronary vasodilation evoked by chemical stimulation of cardiac afferent vagal C fibres in dogs. *J Physiol* **428**:215-232.
85. Clozel JP, Banken L and Roux S (1990b) Aprotinin: an antidote for recombinant tissue-type plasminogen activator (rt-PA) active in vivo. *J Am Coll Cardiol* **16**:507-510.
86. Clozel JP, Veniant M and Osterrieder W (1990c) The structurally novel Ca<sup>2+</sup> channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. *Cardiovasc Drugs Ther* **4**:731-736.
87. Hefti F, Clozel JP and Osterrieder W (1990) Antihypertensive properties of the novel calcium antagonist (1S,2S)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino] ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride in rat models of hypertension. Comparison with verapamil. *Arzneimittelforschung* **40**:417-421.
88. Clozel JP, Kuhn H and Hefti F (1989a) Decreases of vascular hypertrophy in four different types of arteries in spontaneously hypertensive rats. *Am J Med* **87**:92S-95S.
89. Clozel JP, Kuhn H and Hefti F (1989b) Effects of cilazapril on the cerebral circulation in spontaneously hypertensive rats. *Hypertension* **14**:645-651.

90. Clozel JP and Clozel M (1989a) Effects of endothelin on the coronary vascular bed in open-chest dogs. *Circ Res* **65**:1193-1200.
91. Clozel JP, Banken L and Osterrieder W (1989c) Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. *J Cardiovasc Pharmacol* **14**:713-721.
92. Clozel M and Clozel JP (1989b) Effects of endothelin on regional blood flows in squirrel monkeys. *J Pharmacol Exp Ther* **250**:1125-1131.
93. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M and Baumgartner HR (1989) Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. *Science* **245**:186-188.
94. Clozel JP and Fischli W (1989) Cyclosporin-induced hypertension in marmosets: a new model of hypertension sensitive to angiotensin-converting enzyme inhibition. *J Cardiovasc Pharmacol* **14**:77-81.
95. Clozel JP, Kuhn H and Hefti F (1989d) Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. *J Hypertens* **7**:267-275.
96. Clozel JP, Saunier C, Hartemann D, Allam M and Fischli W (1989e) Effects of hypoxia and hypercapnia on atrial natriuretic factor and plasma renin activity in conscious dogs. *Clin Sci (Lond)* **76**:249-254.
97. Clozel JP (1989) Effects of chronic heart failure on the responsiveness to angiotensin I and to angiotensin converting enzyme inhibition with cilazapril in rats. *Br J Clin Pharmacol* **27 Suppl 2**:167S-174S.
98. Fischli W, Hefti F and Clozel JP (1989) Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats. *Br J Clin Pharmacol* **27 Suppl 2**:151S-158S.
99. Clozel JP, Tschopp T, Luedin E and Holvoet P (1989f) Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model. *Circulation* **79**:125-133.
100. Clozel JP, Lengsfeld H, Kuhn H and Baumgartner HR (1988a) Decreased coronary vascular reserve in Watanabe heritable hyperlipidemic rabbits. *Arteriosclerosis* **8**:310-320.
101. Clozel JP and Hefti F (1988) Cilazapril prevents the development of cardiac hypertrophy and the decrease of coronary vascular reserve in spontaneously hypertensive rats. *J Cardiovasc Pharmacol* **11**:568-572.
102. Clozel JP (1988a) Haemodynamic effects of tiapamil and verapamil in conscious rats following chronic myocardial infarction. *Cardiology* **75**:161-169.

103. Clozel JP (1988b) Effects of nitrendipine and cilazapril alone or in combination on hemodynamics and regional blood flows in conscious spontaneously hypertensive rats. *J Cardiovasc Pharmacol* **12**:600-607.
104. Clozel JP, Holvoet P and Tschopp T (1988b) Experimental pulmonary embolus in the rat: a new in vivo model to test thrombolytic drugs. *J Cardiovasc Pharmacol* **12**:520-525.
105. Clozel JP, Holck M, Osterrieder W, Burkard W and Da Prada MD (1987a) Effects of chronic myocardial infarction on responsiveness to isoprenaline and the state of myocardial beta adrenoceptors in rats. *Cardiovasc Res* **21**:688-695.
106. Clozel JP and Hefti F (1987) Effects of chronic therapy with cilazapril, a new angiotensin-converting enzyme inhibitor, on regional blood flows in conscious spontaneously hypertensive rats. *J Cardiovasc Pharmacol* **10**:350-355.
107. Clozel JP, Delorme N, Battistella P, Breda JL and Polu JM (1987b) Hemodynamic effects of intravenous diltiazem in hypoxic pulmonary hypertension. *Chest* **91**:171-175.
108. Clozel M, Hascoet JM, Clozel JP, Monin P and Vert P (1986) Effect of diltiazem on hemodynamics and regional blood flows in the newborn piglet. *Dev Pharmacol Ther* **9**:32-43.
109. Clozel JP, Amend P, Saunier C and Hartemann D (1985a) Cimetidine inhibits the hypoxia-induced increase in cerebral blood flow in dogs. *Crit Care Med* **13**:976-981.
110. du Souich P, Clozel JP, Saunier C, Hartemann D, Schrijen F and Amend P (1985a) The influence of hypoxemia on tritiated digoxin plasma kinetics and tissue distribution in the conscious dog. *Am Rev Respir Dis* **132**:504-509.
111. Clozel JP, Roberts AM, Hoffman JI, Coleridge HM and Coleridge JC (1985b) Vagal chemoreflex coronary vasodilation evoked by stimulating pulmonary C-fibers in dogs. *Circ Res* **57**:450-460.
112. Terrier de La Chaise A, Brembilla-Perrot B, Clozel JP, Cherrier F and Faivre G (1985) [Cardiac electrophysiologic effects of prostacyclin in man]. *Arch Mal Coeur Vaiss* **78**:1156-1162.
113. Brembilla-Perrot B, Terrier de la Chaise A, Clozel J, Cherrier F and Faivre G (1985) Proarrhythmic and antiarrhythmic effects of intravenous prostacyclin in man. *Eur Heart J* **6**:609-614.
114. Danchin N, Clozel JP, Khalife K, Elkik F, Boulay F, Neimann JL and Cherrier F (1985) Prophylactic effect of intravenous tiapamil on methylethylergometrine-induced coronary artery spasm in patients with variant angina: randomized double-blind trial. *Am Heart J* **109**:764-768.
115. Perrot B, Thiel B, Clozel JP, Rizk J, Bara B, Cherrier F and Faivre G (1985) [Diagnostic value of methods of ventricular and auricular stimulation in the evaluation of tachycardia]. *Arch Mal Coeur Vaiss* **78**:569-577.

116. Sautegeau A, Clozel JP, Saunier C and Hartemann D (1985) In vitro effects of hypoxia and (or) hypercapnic acidosis on the myocardial uptake of digoxin. *Can J Physiol Pharmacol* **63**:344-346.
117. du Souich P, Clozel JP, Saunier C, Ong H, Hartemann D, Garcia-Carmona T and Sadoul P (1985b) Influence of hypoxemia and respiratory acidosis on the plasma kinetics and tissue distribution of digoxin in the conscious dog. *Can J Physiol Pharmacol* **63**:72-77.
118. Roux S, Latour JG, Theroux P, Clozel JP and Bourassa MG (1984) Prostaglandin E1 increases myocardial contractility in the conscious dog. *Can J Physiol Pharmacol* **62**:1505-1510.
119. Clozel JP, Billette J, Caille G, Theroux P and Cartier R (1984a) Effects of diltiazem on atrioventricular conduction and arterial blood pressure: correlation with plasma drug concentrations. *Can J Physiol Pharmacol* **62**:1479-1486.
120. Perrot B, Clozel JP, de la Chaise AT, Cherrier F and Faivre G (1984a) Electrophysiological effects of intravenous prostacyclin in man. *Eur Heart J* **5**:883-889.
121. Clozel JP, Danchin N, Genton P, Thomas JL and Cherrier F (1984b) Effects of propranolol and of verapamil on heart rate and blood pressure in hyperthyroidism. *Clin Pharmacol Ther* **36**:64-69.
122. Clozel JP, Caille G, Taeymans Y, Theroux P, Biron P and Trudel F (1984c) High-performance liquid chromatographic determination of diltiazem and six of its metabolites in human urine. *J Pharm Sci* **73**:771-773.
123. Perrot B, Clozel JP and Faivre G (1984b) Effect of adenosine triphosphate on the accessory pathways. *Eur Heart J* **5**:382-393.
124. Newman S, Road J, Bellemare F, Clozel JP, Lavigne CM and Grassino A (1984) Respiratory muscle length measured by sonomicrometry. *J Appl Physiol* **56**:753-764.
125. Clozel JP, Caille G, Taeymans Y, Theroux P, Biron P and Besner JG (1984d) Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. *J Pharm Sci* **73**:207-209.
126. Clozel JP, Theroux P, Caille G and Bourassa MG (1983a) [Calcium antagonists: pharmacological effects and therapeutic indications]. *Union Med Can* **112**:236-240, 284.
127. Clozel JP, Theroux P and Bourassa MG (1983b) Effects of diltiazem on experimental myocardial ischemia and on left ventricular performance. *Circ Res* **52**:1120-1128.
128. Clozel JP and du Souich P (1982) [Respiratory insufficiency and pharmacology of theophylline]. *Bull Eur Physiopathol Respir* **18**:807-810.
129. Clozel JP, Saunier C, Royer-Morot MJ, Royer RJ and Sadoul P (1981) Respiratory acidemia and theophylline pharmacokinetics in the awake dog. *Chest* **80**:631-633.